Bladder cancer is a common malignant tumor in the urinary system. There are still a lot of missed diagnosis of biomarkers for early bladder cancer, so it is necessary to explore new tumor biomarkers to improve the diagnostic rate of bladder cancer. Proteomic workflow can reveal a large number of proteome and metabolome data, providing potential biomarkers for screening early bladder cancer.